Peptazol Injection (Pantoprazole Sodium Sesquihydrate)

Adult dosage

If oral administration of pantoprazole is inappropriate, dissolve the contents of 1 vial of this medicine (equivalent to 40 mg of pantoprazole) in 10 mL of normal saline for injection and administer by direct intravenous injection, or mix this solution with 100 mL of normal saline for injection or 5 % dextrose solution and administer intravenously over 2∼15 minutes. As soon as oral administration becomes possible, discontinue intravenous pantoprazole and switch to oral pantoprazole 40 mg. 1. Duodenal ulcer, gastric ulcer, moderate to severe reflux esophagitis Administer 1 vial of this medicine (equivalent to 40 mg of pantoprazole) intravenously once daily. 2. Zollinger-Ellison syndrome and other pathological hypersecretory conditions - Start with an initial dose of 80 mg daily, then increase or decrease the dose according to gastric acid secretion measurements. - For doses of 80 mg or more, administer the dose in 2 divided doses daily. - Temporary increases to 160 mg or more are possible, but should be used only to the extent needed to control an appropriate amount of acid. - When rapid acid control is required, an initial dose of 2 × 80 mg reduced acid output to the target range (< 10 mEq/h) within one hour in most patients. &#9711; In patients with severe hepatic impairment, the daily dose should be reduced to 20 mg of pantoprazole. &#9711; In elderly patients or patients with renal impairment, the daily dose should not exceed 40 mg of pantoprazole.

This medication should not be used in certain patients. In particular, it should not be administered to patients who have had allergic reactions to this drug or its components, or who have a history of hypersensitivity to benzimidazoles. Additionally, patients currently taking certain medications such as atazanavir, nelfinavir, or rilpivirine should not use this medication concurrently. Various adverse reactions may occur when using this medication. For example, blood-related issues, gastrointestinal pain or diarrhea, respiratory issues, liver function abnormalities, allergic reactions, skin rashes, muscle pain, neurological symptoms, and mental health issues have been reported. Severe cases may result in anaphylactic shock or serious skin disorders, so caution is needed. Regular examinations are required when using this medication long-term. In particular, patients with compromised liver function should reduce the dosage and periodically check liver enzyme levels. Moreover, prolonged use may increase the risk of fractures and electrolyte imbalances such as hypomagnesemia, hence caution is necessary. Since this medication suppresses gastric acid secretion, there may be a slight increase in the risk of bacterial infections in the stomach. If diarrhea persists or worsens, medical consultation should be sought. Dizziness or blurred vision may occur, so caution is necessary when driving or operating machinery. This medication may interact with other drugs; therefore, patients currently taking methotrexate, anticoagulants, or specific antiviral drugs should inform their healthcare provider. Avoid use during the first three months of pregnancy, and use only when the therapeutic benefit is deemed to outweigh the risks during pregnancy. It is also recommended that breastfeeding women do not use this medication. There is insufficient experience in the use of this drug in children and adolescents under 18 years old, so it is advisable not to use it in this population. No specific symptoms have been reported for overdose; however, if problems occur, medical personnel should be notified immediately and symptomatic treatment should be provided. This drug is injected; it must be dissolved in a designated solution prior to use, and the prepared solution should be used within 12 hours. It should be stored in a container that blocks light and sealed to prevent air from entering. Additionally, it is best to store it in a cool place at a temperature below 25 degrees Celsius, and do not use or discard discolored or turbid solutions.

Anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, abdominal pain, diarrhea, constipation, abdominal distension, dyspepsia, gastric polyps, nausea, vomiting, dry mouth, rhinitis, injection site reaction, injection site thrombophlebitis, fever, peripheral edema, pyrexia, elevated bilirubin, liver failure, jaundice, hepatocellular damage, increased liver enzyme levels, arthralgia, myalgia, rhabdomyolysis, bone fractures, headache, dizziness, vision disturbances, dysgeusia, insomnia, sleep disorders, depression, hallucinations, disorientation, confusion, interstitial nephritis, pruritus, skin erythema, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, photosensitivity reaction, gynecomastia, hyperlipidemia, increased lipids, weight changes, hyponatremia, hypomagnesemia, elevated CK, anterior ischemic optic neuropathy, elevated creatine kinase, severe skin reactions, pancreatitis, confusion, decreased mobility, language disorders, increased saliva, vertigo, tinnitus, hypocalcemia, hypokalemia, Clostridium difficile-associated diarrhea, paresthesia, DRESS syndrome, microscopic colitis, systemic lupus erythematosus, cutaneous lupus erythematosus, diarrhea, heartburn

This medication should be stored in a container that can block light and sealed tight to prevent air from entering. It is also advisable to keep it in a cool place at a temperature below 25 degrees Celsius.

Appearance

This medication is a colorless and transparent vial containing a white to almost white dry powder.

Package unit

[Domestic Use] [Export Use 2] 1 vial (46.1mg/vial×1), 10 vials (46.1mg/vial×10) [Export Use 1] 1 vial (45.1mg/vial×1)